UCB and Nodality Enter into a Multi-Year Strategic Collaboration
Brussels, Belgium and South San Francisco, California, USA, February 10, 2012, UCB Pharma S.A. (Euronext Brussels: UCB) and Nodality, Inc. today announced a strategic collaboration utilizing Nodality’s proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds. The agreement establishes a multi-year collaborative investigation focusing initially on immunology disorders. Based on information generated using Nodality’s technology, the agreement also gives UCB the option to engage Nodality to develop companion diagnostics for UCB’s compounds. The terms of the agreement, whose details are not disclosed, include an upfront payment, R&D funding, and success-based milestones if all applicable development, regulatory and commercialization milestones are achieved. In addition, Nodality may be eligible for royalties on future diagnostic sales.
David Parkinson, MD, Chief Executive Officer of Nodality, said, “We are delighted to be working together with UCB’s world class immunology research group to enhance their drug development activities. Based on Nodality’s extensive application of the SCNP platform to malignant and autoimmune diseases, we believe that we will be able to add significant value to UCB’s drug development portfolio. This collaboration is validation of Nodality’s unique technological approach and of the value the SCNP platform technology can bring to pharmaceutical drug development. We look forward to a close and productive working relationship with UCB’s research and development teams."
Ismail Kola, Executive Vice President and President, NewMedicines at UCB said, “We look forward to the Nodality collaboration as we advance UCB’s Research & Development pipeline. This collaboration represents a key component of UCB’s strategy to innovate on the paradigm of drug development through an enhanced understanding of disease pathways and drug mechanisms in order to realize the potential for patient stratification, targeted treatments and improved care for patients.”
For further information UCB
France Nivelle, Global Communications, UCB
T +32.2.559.9178, firstname.lastname@example.org
Laurent Schots, Global Communications, UCB
T +32.2.559.9264, email@example.com
Antje Witte, Investor Relations UCB
T +32.2.559.9414, firstname.lastname@example.org
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 8500 people in over 40 countries, UCB produced revenue of EUR 3.22 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).
Nodality is a private, South San Francisco-based biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling technology platform. Through its ability to functionally characterize cell signaling networks at the single cell level of resolution Nodality is committed to the biological characterization of individual patients to optimally match them with biologically-targeted treatments. Visit www.nodality.com to learn more.
Forward looking statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
Stay up-to-date on the latest news and information from UCB